Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wholesalers Could Benefit From Generics-Heavy Medicare Rx Benefit - Exec

Executive Summary

Drug wholesalers would benefit from the implementation of a Medicare drug benefit if it includes incentives for using generic drugs, AmeriSource CEO David Yost told analysts at the Bear Stearns health care conference in New York City Sept. 16.

You may also be interested in...



Cardinal Seeking Med/Surg Margin Surge, Offers Allegiance $5.4 Bil.

Cardinal's 12-month engagement with Bergen so whetted the Ohio wholesaler's tastes for the medical/surgical supply margins that it is offering $4.5 bil. in Cardinal stock to buy the largest position in the field through the acquisition of the Allegiance hospital supply business.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
UsernamePublicRestriction

Register

PS034938

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel